MedPath

Comparative Study of microRNA Changes in Patients With Reactive Lymphoid Hyperplasia and Malignant Lymphoma

Conditions
Hyperplasia Lymphoid Reactive
Lymphoma
Registration Number
NCT03167476
Lead Sponsor
University of Electronic Science and Technology of China
Brief Summary

The objectives are to:

1. validate a panel of tissue-specific miRNAs that are differentially expressed in the tissue of patients with and without reactive hyperplasia and lymphoma.

2. investigate the physiological range of the miRNA panel in lymphoma and reactive hyperplasia subjects.

3. investigate the dysregulation of miRNA panel and their prognostic and predictive values in clinical outcomes to identifying patients with malignant lymphoma or reactive hyperplasia.

The objectives are to:

1. validate a panel of tissue-specific miRNAs that are differentially expressed in the tissue of patients with and without reactive hyperplasia and lymphoma.

2. investigate the physiological range of the miRNA panel in lymphoma and reactive hyperplasia subjects.

3. investigate the dysregulation of miRNA panel and their prognostic and predictive values in clinical outcomes to identifying patients with malignant lymphoma or reactive hyperplasia.

This trial involves tissue samples diagnosed as lymphoma and reactive hyperplasia. The investigators will develop panels of miRNAs that are specific biomarkers of lymphoma, and assist clinical outcomes with these miRNAs.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
200
Inclusion Criteria
  • Adults 18 years and above
  • Has condition related to lymphoma or reactive lymphoid hyperplasia
Exclusion Criteria
  • Age below 18 years
  • Known pregnancy
  • lymph tissue cannot be accessed

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The concentration of miRNA expression quantitated in absolute copy numbers and their correlation in patients with reactive hyperplasia and lymphoma.Three years

The concentration of tissue miRNAs in absolute quantification in comparison to reactive hyperplasia and lymphoma. To investigate the potential prognosis of lymphoma by the expression difference of the miRNA panel. Sensitivity, specificity and the potential scopes of selected miRNA in the miRNA panel to distinguish hyperplasia and lymphoma and against standard clinical outcome.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

University of Electronic Science and Technology of China

🇨🇳

Chengdu, Sichuan, China

© Copyright 2025. All Rights Reserved by MedPath